Status:
UNKNOWN
Efficiency of Methotrexate and Tofacitinib in Mild and Moderate Patients
Lead Sponsor:
Shanghai Zhongshan Hospital
Conditions:
Takayasu Arteritis
Methotrexate
Eligibility:
All Genders
14-100 years
Phase:
PHASE4
Brief Summary
Takayasu arteritis (TAK) is a rare chronic inflammatory arteritis, which lacks an effective well-accepted intervention strategy. Here we tried to classify TAK patients in 3 levels, including mild, mod...
Detailed Description
The Takayasu arteritis (TAK) is a rare chronic inflammatory arteritis, which lacks effective well-accepted intervention strategy. Previous studies have revealed that methoxamine, tofacitinib, adalimum...
Eligibility Criteria
Inclusion
- age≥14 years;
- active status: Kerr score≥ 2;
- mild and moderate:
- Blood pressure (maximum) \< 180/110mmHg;
- 1-2 branches with the stenotic rate \< 70% involved;
- mildly ischemic manifestation relative to activity but relieve after rest;
- no or low degree of organ insufficiency: NYHF I\~II; eGFR (MRDR) ≥ 60ml/min;
Exclusion
- Severe organ insufficiency;
- Acute or chronic active infections including tuberculosis, hepatitis virus, etc.;
- Other autoimmune diseases including systemic lupus erythematosus, Behcet disease, IgG4 relative disease;
- malignant tumors;
- history of severe drug allergy;
- successive twice relapse occurs even after the intervention adjustment ( for the benefits of patients)
Key Trial Info
Start Date :
March 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT04299971
Start Date
March 1 2020
End Date
December 31 2023
Last Update
June 12 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lindi Jiang
Shanghai, China, 200032